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Thalidomide is a potent developmental toxicant that induces a
range of birth defects, notably severe limb malformations. To
unravel the molecular mechanisms underpinning the teratogenic
effects of thalidomide, we used microarrays to study transcrip-
tomic changes induced by thalidomide in an in vitro model based
on the differentiation of mouse embryonic stem cells (mESCs), and
published the major ﬁndings in a research article entitled
“Thalidomide induced early gene expression perturbations indi-
cative of human embryopathy in mouse embryonic stem cells” [1].
The data presented herein contains complementary information
related to the aforementioned research article.
Published by Elsevier Inc. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableSubject area BiologyMore speciﬁc
subject areaToxicogenomicsType of data 1) Processed microarray data in .CEL format
2) Excel spreadsheet ﬁles listing identiﬁed genes, GO terms and functional clustersen access article under the CC BY license
/j.taap.2015.05.009
l, MD 20708, USA. Tel.: þ1 301 796 0580.
ao).
X. Gao et al. / Data in Brief 4 (2015) 199–202200How data was
acquiredMicroarray data generated on Affymetrix Mouse Gene 2.0 ST ArrayData format Processed or analyzed
Experimental factors Induction of spontaneous differentiation was achieved through embryoid body (EB) formation in
hanging drop culture following a procedure adapted from De Smedt et al.[2]
Experimental
featuresCells were collected at 24, 48, and 72 h after exposure to 0.25 mM thalidomide. Total RNA (50 ng)
were preprocessed using the Affymetrix GeneChip WT PLUS Reagent Kit and hybridized onto the
Affymetrix Mouse Gene 2.0 ST ArrayData source location Laurel, MD, USA
Data accessibility The analyzed data is with this article. Processed microarray data (.CEL ﬁles) can be accessed at Gene
Expression Omnibus with accession number GSE61306 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE61306)Value of the data The data represent the ﬁrst toxicogenomic study on thalidomide using mouse embryonic stem
cells [1]. The gene expression data provide insights into mechanisms of thalidomide embryotoxicity [1].
 The functions and pathways associated with thalidomide-impacted genes conform to known
thalidomide clinical outcomes [1].
 The data suggest that transcriptomics coupled with mouse embryonic stem cells is a valuable
model for developmental toxicity testing [1].
1. Experimental design, materials and methods
1.1. Materials
(7)-Thalidomide ((RS)-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione) and all other
chemicals used in this study were of molecular biology grade and were obtained from Sigma-
Aldrich (St. Louis, MO) unless otherwise stated.
1.2. Pluripotent mouse embryonic stem cell culture
Pluripotent ESGRO Complete Adapted C57BL/6 mESCs, which have been pre-adapted to serum-free
and feeder-free culture condition, were obtained from EMD Millipore (Billerica, MA) at passage 12
(with 80% normal male mouse karyotype). The cells were seeded in cell culture ﬂasks (Nunc, Roskilde,
Denmark) coated with 0.1% gelatin solution (EMD Millipore), and maintained at 37 1C in a 5% CO2
humidiﬁed incubator at standard densities (i.e., between 5104/cm2 and 5105/cm2) in ESGRO
Complete Plus Clonal Grade Medium (EMD Millipore). The medium contains leukemia inhibitory
factor (LIF), bone morphogenic protein 4 (BMP-4), and a glycogen synthase kinase-3b inhibitor
(GSK3b-I) to help maintain pluripotency and self-renewal of the ESCs. Cells were passaged every 2–3
days (when reaching 60% conﬂuence) with ESGRO Complete Accutase (EMD Millipore) at about 1:6
ratio. C57BL/6 mESCs maintain a stable karyotype under the above passaging condition. The cells used
in the current study were at passage 18.
1.3. Mouse embryonic stem cell differentiation through embryoid body formation
Induction of differentiation was achieved through embryoid body (EB) formation via hanging drop
culture following a procedure adapted from De Smedt et al. [2]. In brief, stem cells were thawed and a
suspension was prepared at a concentration of 3.75104 cells/ml in ESGRO Complete Basal Medium
(EMD Millipore), which does not contain LIP, BMP-4, or GSK3b-I. About 50 drops (each of 20 ml) of the
cell suspension were placed onto the inner side of the lid of a 10-cm Petri dish ﬁlled with 5 ml
phosphate buffered saline (PBS; EMD Millipore) and incubated at 37 1C and 5% CO2 in a humidiﬁed
atmosphere. After 3 days, EBs formed in the hanging drops (Ø330–350 μm) were subsequently
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thalidomide exposure.1.4. Thalidomide exposure and RNA isolation
ESC differentiation cultures were exposed from the EB stage at day 3 onwards to 0.25 mM thalidomide
or vehicle (0.25% DMSO) for 3 days. Preliminary results showed that DMSO at 0.25% (v/v) had no
signiﬁcant effect on gene expression during C57BL/6 ESC differentiation under the condition used in the
study (data not shown).Thalidomide-exposed cultures and vehicle controls were collected at 24 h, 48 h,
and 72 h (culture day 4, 5, and 6). Three biological replicates were used for each condition. Treatment with
thalidomide did not affect EB sizes (data not shown). EBs were lysed in RLT buffer (Qiagen; Valencia, CA)
supplemented with β-mercaptoethanol, homogenized by QIAshredder (Qiagen), and kept in a 80 1C
freezer until further processing. Total RNAwas isolated on the EZ1 Advanced XL (Qiagen) automated RNA
puriﬁcation instrument using the EZ1 RNA Cell Mini Kit (Qiagen) following the manufacturer's protocol,
including an on-column DNase digestion. RNA concentration and purity (260/280 ratio) were measured
with the NanoDrop 2000 UV–Vis spectrophotometer (NanoDrop Products, Wilmington, DE). Integrity of
RNA samples was assessed by the Agilent 2100 Bioanalyzer (Santa Clara, CA) with the RNA 6000 Nano
Reagent Kit from the same manufacturer.1.5. RNA processing and microarray experiment
The total RNA samples were preprocessed for hybridization to Mouse Gene 2.0 ST Array (Affymetrix,
Santa Clara, CA) using the GeneChip WT PLUS Reagent Kit (Affymetrix) following the manufacturer's
protocol. In brief, 50 ng of total RNA was used to generate ﬁrst strand cDNA using reverse transcriptase
and primers containing a T7 promoter sequence. The single-stranded cDNA was then converted to
double-stranded cDNA by using DNA polymerase and RNase H to simultaneously degrade the RNA and
synthesize second-strand cDNA. Complimentary RNA (cRNA) was synthesized and ampliﬁed by in vitro
transcription (IVT) of the second-stranded cDNA template using T7 RNA polymerase. Subsequently, sense-
strand cDNA was synthesized by the reverse transcription of cRNA with incorporated deoxyuridine
triphosphate (dUTP). Puriﬁed, sense-strand cDNA was fragmented by uracil-DNA glycosylase (UDG) and
apurinic/apyrimidinic endonuclease 1 (APE 1) at the unnatural dUTP residues and labeled by terminal
deoxynucleotidyl transferase (TdT) using the Affymetrix proprietary DNA Labeling Reagent that is
covalently linked to biotin. Subsequent hybridization, wash, and staining were carried out using the
Affymetrix GeneChip Hybridization, Wash, and Stain Kit and the manufacturer's protocols were followed.
Brieﬂy, each fragmented and labeled sense-strand cDNA target sample (approximately 3.5 mg) was
individually hybridized to a GeneChip Mouse Gene 2.0 ST Array at 45 1C for 16 h in Affymetrix GeneChip
Hybridization Oven 645. After hybridization, the array chips were stained andwashed using an Affymetrix
Fluidics Station 450. The chips were then scanned on Affymetrix GeneChip Scanner 3000 7G and the
image (.DAT) ﬁles were preprocessed using the Affymetrix GeneChip Command Console (AGCC) software
v.4.0 to generate cell intensity (.CEL) ﬁles. Prior to data analysis, all arrays referred to in this study were
assessed for data quality using the Affymetrix Expression Console software v.1.3 and all quality assessment
metrics (including spike-in controls during target preparation and hybridization) were found within
boundaries. The data set has been deposited in Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/) of the National Center for Biotechnology Information with accession number GSE61306.1.6. Data processing and statistical analysis
The values of individual probes belonging to one probe set in .CEL ﬁles were summarized using the
robust multi-array average (RMA) algorithm [3] embedded in the Expression Console software v.1.3
(Affymetrix), which comprises of convolution background correction, quantile normalization, and
median polish summarization. Subsequently, differentially expressed genes (DEGs) were selected
using one-way analysis of variance (ANOVA) using the Affymetrix Transcriptome Analysis Console
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was used for selection of DEGs with cutoff values indicated in the text.
1.7. Gene ontology analysis
The signiﬁcantly regulated genes were subjected to gene ontology (GO) using the Database for
Annotation, Visualization, and Integrated Discovery (DAVID) [4,5] to ﬁnd overrepresentations of GO
terms in the biological process (BP) category at all levels (GOTERM_BP_ALL) and associated clusters.
As background, the Mus musculus (mouse) whole genome was used. Statistical enrichment was
determined using default settings in DAVID.2. Deposited data
The processed data (.CEL ﬁles) can be found here: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE61306.Conﬂict of interest
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